Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Truce reached in transgenic mouse battle

After nearly three years of laboratory and legal rivalry, Cell Genesys Inc. (CEGE) and GenPharm International last week announced that they will cross-license their patents involving transgenic mice that produce human antibodies, and that CEGE will pay GenPharm up to

Read the full 404 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers